Press & News

The next generation biopharmaceuticals

Press releases

2019-09-20

Affibody and GE Healthcare to Collaborate on Development of Affibody® PET Imaging Tracers

Solna, Sweden, September 20, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced a strategic collaboration with GE Healthcare to develop and commercialize Affibody®-based PET imaging tracers, with initial focus on HER2 and PD-L1. Financial terms were not disclosed.[read more]

Older press releases

2019-08-23

Interim Report – January to June 2019

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the second quarter of 2019.[read more]

2019-07-16

Affibody Announces Interim Analysis in Phase 2 Psoriasis Trial of ABY-035

Solna, Sweden, July 16, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced the completion of the planned 12 week interim analysis in the Company’s Phase 2 proof-of-concept study of...[read more]

2019-06-17

Affibody to Present at Affinity 2019

Solna, Sweden, June 17, 2019. Affibody AB (“Affibody”), a clinical stage biotech company, today announced that Prof. Fredrik Frejd, CSO, will present at the Affinity 2019 conference in June.[read more]

Affibodys latest Press releases

2020-02-21

Year End Report 2019

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotechcompany focused on developing next generation biopharmaceuticals based on...[read more]

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

Interim Report Q1 2020 (May 15, 2020)

Investor information